BACKGROUND: Solid pseudopapillary neoplasms (SPNs) of the pancreas are rare malignant tumors that can be sampled via endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). Although diagnosing SPNs can be straightforward in cases with a classic morphology and a typical immunoprofile, challenges can occur with morphologic variants or limited specimens. Recently, 2 immunohistochemical stains, SRY-related high-mobility group box 11 (SOX-11) and transcription factor E3 (TFE3), have been demonstrated to be highly sensitive and specific for SPNs in pancreatic resection specimens.
INTRODUCTION
Solid pseudopapillary neoplasms (SPNs) of the pancreas are rare indolent but malignant tumors that constitute less than 2% of all exocrine pancreatic tumors. These tumors classically occur in young women and typically present as a well-circumscribed, solitary lesion that may be located anywhere within the pancreas. Complete surgical resection is curative for most patients, although metastases are reported in 5% to 15% of cases. 1 Although these tumors can be suspected on the basis of clinical and radiographic findings, the diagnosis is made on tissue, with specimens obtained through endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) or surgical resection.
In cytologic evaluations of EUS-FNA specimens, SPNs tend to have hypercellular smears with a monotonous population of cells with bland, smoothly contoured or grooved nuclei, fine chromatin, and inconspicuous nucleoli. The cytoplasm is typically delicate with indistinct borders. These cells can be found in loosely cohesive groups, as isolated cells, and in characteristic papillary clusters with cells arranged around vascular structures thickened by myxoid or hyaline material. 2 The differential diagnosis includes neuroendocrine tumors (NETs) of the pancreas, pancreatoblastomas, and acinar cell carcinomas, all of which may show cytomorphologic overlap. Immunocytochemical staining can help: the majority of SPNs exhibit aberrant nuclear b-catenin staining, which has become one of the most useful markers in the diagnosis of this neoplasm. However, up to 12% of acinar cell carcinomas, 8% of NETs, and 100% of pancreatoblastomas have also been reported to exhibit nuclear expression of bcatenin, decreasing its specificity for SPNs. [3] [4] [5] Because of the potential overlap, the diagnosis of SPN often relies on the integration of clinical and morphological features as well as a panel of immunohistochemical stains; even so, a definitive diagnosis can be difficult to make in selected cases, especially if there is little material for evaluation or if the morphologic features are not considered classic for this diagnosis. We recently identified 2 immunohistochemical stains, SRY-related high-mobility group box 11 (SOX-11) and transcription factor E3 (TFE3), that in combination were found to be highly sensitive and specific for the diagnosis of SPNs on surgical resection. 6 SOX-11 is a member of the SOX family of transcription factors, which belongs to a superfamily of genes containing a sequence known as the high mobility group box that is involved in sex determination. Many members of the SOX family have been identified and have been shown to play distinct roles in development. SOX-11 is localized on chromosome 2p25.3 and has been shown to be critical in embryonic neurogenesis and neuronal cell fate. 7, 8 SOX-11 gene mutations have also been previously associated with malignancies such as mantle cell lymphoma and gliomas. 9, 10 More recently, SOX-11 messenger RNA has shown to be consistently increased in SPNs by RNA microarray analysis.
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TFE3 is a member of the microphthalmia family of transcription factors (ie, the MiT family), which are considered oncogenes. TFE3 specifically has been implicated in the biogenesis of lysosomes and autophagosomes and in the clearance of cellular debris, and it is also associated with alveolar soft part sarcoma and translocationassociated renal cell carcinoma. 12, 13 Overexpression of microphthalmia-associated transcription factor, a different member of the MiT family that is associated with melanoma, has been associated with enhanced Wnt signaling after vesicular trafficking reprogramming. 13 It is possible that overexpression of other members of the MiT family such as TFE3 could also alter the Wnt/b-catenin signaling pathway, which is known to be altered in SPNs. 13, 14 When SOX-11 and TFE3 were evaluated in the context of SPNs on surgical resection, the 2 markers in combination were highly sensitive and specific for the diagnosis of SPN 6 ; however, these 2 stains have not yet been explored in the context of cytology. EUS-FNA has been established as a useful method for evaluating pancreatic lesions, but when pancreatic neoplasms are sampled by EUS-FNA, the quantity of the tissue biopsied is by definition less than what can be evaluated by surgical excision, and architectural cues can be more challenging to interpret. 15 In this study,
we assessed whether SOX-11 and TFE3 would be useful in the diagnosis of SPNs in EUS-FNA specimens.
MATERIALS AND METHODS
This study was approved by the institutional review board at Duke University Medical Center. The Duke pathology databases were searched from 2000 to 2016, and 31 cases of resected SPNs were retrieved. Among these 31 cases, a pathologist board-certified in cytology (W.C.F.) identified 13 with corresponding EUS-FNA specimens taken at Duke with sufficient material in the cell block for further evaluation. In addition, 13 cases of other pancreatic tumors with sufficient cell block material for further analysis (11 NETs, 1 pancreatoblastoma, and 1 acinar cell carcinoma), identified by the same pathologist, were used as controls. Demographic information was collected from the patients' electronic medical records. Each of the 26 total cell blocks was subsequently stained with SOX-11, TFE3, and bcatenin. The hematoxylin-eosin-stained sections from each case were matched with the corresponding stained slides. The cases were then de-identified and reviewed by 2 boardcertified pathologists, one with a specialty in cytopathology and another with a specialty in gastrointestinal pathology (W.C.F. and X.Z., respectively). The SOX-11, TFE3, and b-catenin immunocytochemical stains were scored independently by both pathologists in a masked manner. All immunohistochemistry was performed on a Leica Biosystems Bond III automated stainer (Buffalo Grove, Illinois) with 5-lm-thick formalin-fixed, paraffin-embedded tissue sections mounted on positively charged slides. The
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Novocastra Refine detection kit was used for antigen detection for TFE3, the Bond Refine horseradish peroxidase detection kit (Leica Biosystems) was used for antigen detection for SOX-11, and antigen detection for b-catenin was also accomplished with the Bond Refine horseradish peroxidase detection kit (Leica Biosystems). The antibodies used for immunohistochemistry are summarized in Table 1 . Hematoxylin was used as the counterstain.
SOX-11 and TFE3 nuclear immunoreactivity was scored from 0 to 31, and cytoplasmic staining was ignored. Tumors showing nuclear staining that was readily apparent at a low-power magnification (a 43 objective) were scored as strongly positive (31), and those showing nuclear staining that was readily apparent at an intermediate magnification (a 103 objective) were scored as moderately positive (21) . The tumors that showed weak nuclear staining in at least 5% of the tumor nuclei that was apparent only at a high magnification (20-403 objectives) were scored as weakly positive (11) . Tumors that exhibited no staining or showed weak staining (11) in less than 5% of the tumor nuclei were scored as negative (0). b-Catenin immunoreactivity was scored as either positive or negative. Positive immunoreactivity demonstrated strong nuclear and cytoplasmic positivity. Tumors with cytoplasmic/membranous staining in the absence of nuclear immunoreactivity were considered negative.
RESULTS
All 13 EUS-FNA specimens of SPNs were from female patients, who had an age range at diagnosis of 17 to 56 years and a mean age at diagnosis of 32 years. None of these patients developed recurrence after resection, with follow-up times ranging from less than 1 year to more than 10 years after surgery. Of the 13 SPN specimens, all of which were confirmed to be SPNs on surgical resection, 11 were initially diagnosed as SPNs during the initial cytologic evaluation. The remaining 2 were initially diagnosed as a paraganglioma and a neuroendocrine neoplasm with a focal papillary architecture. Eleven of these 13 SPN cases were initially evaluated with the aid of immunocytochemical stains, and 2 were evaluated with cytomorphology alone. Both of the cases evaluated with cytomorphology alone were diagnosed as SPNs by cytology and on surgical resection.
Nuclear immunoreactivity for SOX-11 ( Table 2 ) was present in all 13 of the SPN EUS-FNA samples and in none of the control cases, and this resulted in a sensitivity of 100%, a specificity of 100%, a positive predictive value (PPV) of 1, and a negative predictive value (NPV) of 1. Ten of the 13 cases (76.9%) exhibited strong nuclear expression (31 staining), and 3 of the 13 cases (23.1%) exhibited moderate nuclear expression (21) . Nuclear immunoreactivity for TFE3 (Table 2 ) was seen in 9 of the 13 SPN EUS-FNA samples and in none of the control cases; this resulted in a sensitivity of 69.2%, a specificity of 100%, a PPV of 1, and an NPV of 0.765. Six of the 13 cases (46.2%) exhibited moderate nuclear expression (21), 3 of the 13 cases (23.1%) exhibited weak nuclear staining (11) , and 4 of the 13 cases (30.8%) were negative (0). Aberrant nuclear and cytoplasmic staining for b-catenin (Table 2) was present in all 13 of the SPN EUS-FNA samples and in 1 of the 13 control cases. This resulted in a sensitivity of 100%, a specificity of 92.3%, a PPV of 0.929, and an NPV of 1. The non-SPN control case that was positive for b-catenin was the case of pancreatoblastoma.
DISCUSSION
The diagnosis of SPNs on the basis of EUS-FNA often relies on a combination of clinical, morphologic, and immunocytochemical studies because of the morphologic overlap with other pancreatic neoplasms such as NETs, acinar cell carcinomas, and pancreatoblastomas. Despite the often limited material available, EUS-FNA has been found to be an effective modality for the diagnosis of SPNs in multiple studies, with an accuracy ranging from 75% to 100%. [16] [17] [18] The discovery that 90% of SPNs contain a mutation in exon 3 of the b-catenin gene, which consistently leads to abnormal localization of b-catenin in the nucleus that Abbreviations: SOX-11, SRY-related high-mobility group box 11; TFE3, transcription factor E3.
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can be highlighted by immunohistochemistry, 14 has been
helpful. An immunohistochemical panel using b-catenin and E-cadherin has been shown to be particularly useful in differentiating SPNs from NETs with EUS-FNA. 19, 20 However, both of these stains have their limitations as well. A subset of non-SPN pancreatic tumors also demonstrate this abnormal localization of b-catenin. In particular, pancreatoblastoma has been shown to exhibit nuclear/cytoplasmic expression of b-catenin in the majority of tumors. 5 E-cadherin is absent in SPNs and positive in the majority of NETs, but it is also positive in benign glandular cells that are often also sampled with EUS-FNA. 21 Thus, interpretative challenges can arise in cases with limited lesional material or abundant contaminating benign elements. Two additional immunohistochemical markers commonly used to differentiate SPNs from NETs are synaptophysin and chromogranin; however, studies have shown that although these stains are highly sensitive for NETs, they lack specificity. Synaptophysin, in particular, though reported to be positive in up to 100% of NETs, has also been seen in the majority of SPNs. 4, 22 Chromogranin, though showing increased specificity for NETs in comparison with synaptophysin in some studies, 22, 23 has also been reported to show at least focal expression in up to 100% of SPNs and in more than 30% of acinar cell carcinomas in others. 4, 24 We recently identified 2 additional immunohistochemical stains, SOX-11 and TFE3, that appear to be both sensitive and specific for SPNs on surgical resection. 6 In this study, we explore these 2 stains in the context of cytology and suggest that SOX-11 may be a useful adjunct in the differential diagnosis of SPN with EUS-FNA.
SOX-11 is known to be expressed in hematopoietic and glial malignancies such as mantle cell lymphoma and astrocytic gliomas 9, 10 ; however, its role in solid tumors such as SPNs is still unknown. In a recent publication, Li et al 11 reported that according to a microarray analysis, SOX-11 was found to be exclusively expressed in SPNs in comparison with normal pancreas, pancreatic adenocarcinomas, and pancreatic NETs. 25 Exploring surgically resected SPNs, we found that SOX-11 alone showed a sensitivity of 100% and a specificity of 84%. 6 When SOX-11
was investigated in the current study, nuclear immunoreactivity for SOX-11 was present in all 13 EUS-FNA specimens of SPNs and in no control cases. The cases that were positive demonstrated easily interpretable staining, with 10 of 13 cases (76.9%) exhibiting strong nuclear expression (31 staining) and 3 of 13 cases (23.1%) exhibiting moderate nuclear expression (21; Table 2 and Fig. 1 ). TFE3 has been explored in tumors such as alveolar soft part sarcomas and translocation-associated renal cell carcinomas, but it has had limited evaluation in SPNs. Argani et al 12 investigated the immunoexpression of TFE3 in a range of tumors and found no expression of TFE3 in 8 SPN cases. In the current study, nuclear immunoreactivity for TFE3 was noted in the majority of the SPN samples in accordance with our prior resection results. 6 However, it was not as frequently expressed as SOX-11, with only 9 of 13 SPN samples positive for TFE3. No control cases stained positively for TFE3. The intensity of staining was also less than that noted with SOX-11, with 6 of 13 cases (46.2%) exhibiting moderate nuclear expression (21), 3 of 13 cases (23.1%) exhibiting weak nuclear staining (11) , and 4 of 13 cases (30.8%) exhibiting no staining (0; Table  2 and Fig. 1 ). The differences in the immunoexpression of TFE3 between the current study and Argani et al's study may be due to the use of different antibodies. Why TFE3 appears to be expressed in SPNs remains to be determined, but the association of other MiT family members with the Wnt signaling pathway suggests an oncogenic mechanism in this tumor, which is also known to have b-catenin mutations that affect the Wnt signaling pathway. Evaluated in surgical resection specimens, TFE3 improved the specificity for SPNs when it was used in combination with SOX-11. However, in the current study, SOX-11 alone proved to be most useful for evaluating EUS-FNA specimens. The increased specificity of SOX-11 in cell block material in comparison with our prior analysis of surgical resection specimens may be due to the more limited quantity of material available in cell block preparations, which contain less uninvolved tissue that could complicate interpretation. Because cell block material often yields a limited number of unstained slides available for immunocytochemical evaluation, it is helpful that TFE3 can be omitted from the workup without compromising the sensitivity for identifying SPNs.
Two of the SPN cases were initially misdiagnosed with EUS-FNA. One case was diagnosed initially as a paraganglioma, and the other was diagnosed initially as a NET. Both of these cases were positive for synaptophysin and chromogranin. The case diagnosed as a paraganglioma also showed weak staining for neurofilament protein and scattered staining for S100, and it was initially thought to be a mass located between the liver and the pancreas; this likely affected the initial diagnosis of paraganglioma. It was only , and (P) b-catenin. All photomicrographs were taken at a magnification of 3200. EUS-FNA indicates endoscopic ultrasound-guided fine-needle aspiration; SOX-11, SRY-related high-mobility group box 11; SPN, solid pseudopapillary neoplasm; TFE3, transcription factor E3.
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November 2017 subsequent imaging that confirmed the mass to be arising from the pancreas. In the cytologic evaluation, the smears were hypocellular, although the cell block contained abundant material, which in retrospect demonstrated a prominent pseudopapillary architecture. The case initially misdiagnosed as a neuroendocrine neoplasm exhibited highly cellular smears with areas with a more solid and acinar architecture; papillary foci were present but were less prominent. Neither case was worked up with b-catenin during the initial evaluation, but both were subsequently found to express nuclear b-catenin staining in the cell block material afterward. Both of these cases were also positive for both SOX-11 and TFE3.
b-catenin was positive in 13 of 13 SPNs and in 1 of 13 non-SPNs; this confirmed the results of previous studies noting its high sensitivity and relatively high specificity for this entity. The single non-SPN that exhibited positive staining for b-catenin was the pancreatoblastoma. The pancreatoblastoma exhibited patchy and strong nuclear and cytoplasmic staining for b-catenin (Fig. 1) , with staining present in areas that did not exhibit the morphology of squamous corpuscles. Although most b-catenin positivity in pancreatoblastomas has been reported in the squamous corpuscles, positive staining has also been noted in areas with solid sheets or acinar/ductular differentiation. 5 In conclusion, SOX-11 exhibits very high sensitivity and specificity for SPNs in EUS-FNA specimens. TFE3, though demonstrating very high specificity, shows only moderate sensitivity. Although larger scale studies are needed to confirm these results and explore the mechanism behind these findings, we have determined in the current study that SOX-11 may have great utility as an immunocytochemical stain in distinguishing SPNs from other pancreatic neoplasms in EUS-FNA specimens. Because SOX-11 immunohistochemistry is readily available in most tertiary pathology laboratories, it will be practical to add this to the workup when SPN is within the differential diagnosis.
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